Package Leaflet: Information for the User
Grumabix 250 mgfilm-coated tabletsEFG
abiraterone acetate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Grumabix contains the active substance abiraterone acetate. It is used for the treatment of prostate cancer in adult men that has spread to other parts of the body. This medicine stops your body from making testosterone; this can slow down the growth of your prostate cancer.
When this medicine is prescribed in the early stages of the disease and you are still responding to hormone treatment, it is used together with treatment to lower testosterone levels (androgen deprivation therapy).
When you take this medicine, your doctor will also prescribe another medicine called prednisone or prednisolone to reduce the risk of high blood pressure, fluid retention, or low potassium levels in your blood.
Do not take Grumabix
Do not take this medicine if any of the above applies to you. If you are in doubt, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before starting treatment with this medicine:
Tell your doctor if you have been told you have any heart or blood vessel disorder, including heart rhythm problems (arrhythmia), or if you are being treated with medicines for these disorders.
Tell your doctor if you have yellowing of the skin or eyes, dark urine, or severe nausea or vomiting, as these can be signs or symptoms of liver problems. Rarely, acute liver failure (a sudden severe liver disorder) can occur, which can be life-threatening.
A decrease in red blood cell count, reduced sexual desire, and cases of muscle weakness and/or muscle pain may occur.
This medicine must not be taken in combination with Ra-223 due to a possible increased risk of bone fracture or death.
If you plan to take Ra-223 after treatment with this medicine and prednisone/prednisolone, you must wait 5 days before starting treatment with Ra-223.
If you are unsure if any of the above applies to you, consult your doctor or pharmacist before taking this medicine.
Blood tests
This medicine may affect your liver even if you do not have any symptoms. While you are taking this medicine, your doctor will regularly perform blood tests to check for any effect on your liver.
Children and adolescents
This medicine must not be used in children and adolescents. If a child or adolescent accidentally ingests this medicine, they should go to the hospital immediately and bring this leaflet with them to show to the emergency doctor.
Other medicines and Grumabix
Consult your doctor or pharmacist before taking any other medicine.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is important because this medicine can increase the effects of a number of medicines, including medicines for the heart, sedatives, some medicines for diabetes, herbal medicines (e.g., St. John's Wort), and others. Your doctor may consider changing the dose of these medicines. Also, some medicines may increase or decrease the effects of this medicine. This can lead to side effects or this medicine may not work as well as it should.
Androgen deprivation therapy may increase the risk of heart rhythm problems. Tell your doctor if you are being treated with medicines
Consult your doctor if you are taking any of the medicines listed above.
Grumabix with food
Pregnancy and breastfeeding
This medicine is not indicated in women.
Driving and using machines
It is unlikely that this medicine will affect your ability to drive or use tools or machines.
Grumabix contains lactose and sodium
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
This medicine contains 5.88 mg of sodium (the main component of cooking/table salt) in each tablet. This is equivalent to 0.3% of the maximum daily intake of sodium recommended for an adult.
Follow exactly the instructions of administration of this medicine given to you by your doctor. If you are in doubt, consult your doctor or pharmacist again.
How much to take
The recommended dose is 1,000 mg (four tablets) once a day.
How to take this medicine
It is also possible that your doctor will prescribe other medicines while you are taking this medicine and prednisone or prednisolone.
If you take more Grumabix than you should
If you take more than you should, consult your doctor or go to the hospital immediately.
If you forget to take Grumabix
If you stop taking Grumabix
Do not stop taking this medicine or prednisone or prednisolone unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking this medicine and contact your doctor immediately if you experience any of the following:
Other side effects are:
Very common(may affect more than 1 in 10 people):
Fluid retention in the legs or feet, low potassium levels in the blood, elevated liver function tests, high blood pressure, urinary tract infection, diarrhea.
Common(may affect up to 1 in 10 people):
High levels of fats in the blood, chest pain, irregular heartbeat (atrial fibrillation), heart failure, rapid heartbeat, severe infections called sepsis, bone fractures, indigestion, blood in the urine, skin rash.
Uncommon(may affect up to 1 in 100 people):
Problems with the adrenal glands (related to problems with salt and water), abnormal heart rhythm (arrhythmia), muscle weakness and/or muscle pain.
Rare(may affect up to 1 in 1,000 people):
Lung irritation (also called allergic alveolitis). Liver failure (also called acute liver failure).
Not known(frequency cannot be estimated from the available data):
Heart attack, changes in the electrocardiogram (ECG) (prolonged QT), and severe allergic reactions with difficulty swallowing or breathing, face, lips, tongue, or throat swelling, or itchy rash.
Bone density loss may occur in men receiving treatment for prostate cancer. This medicine in combination with prednisone or prednisolone may increase this bone density loss.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines and Healthcare Products Agency (AEMPS) website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Composition of Grumabix
Each film-coated tablet contains 250 mg of abiraterone acetate.
Appearance and packaging
They are white or almost white, oval, biconvex film-coated tablets, 16 mm in length, with 250 engraved on one side.
Grumabix 250 mg film-coated tablets EFG are available in OPA/Aluminum/PVC/Aluminum blisters inserted in a cardboard box. Each box contains 120 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder
Adamed Pharma S.A.
Pienków, ul. M. Adamkiewicza 6A
05-152 Czosnów
Poland
Manufacturer
Adamed Pharma S.A.
ul. Marszalka Józefa Pilsudskiego 5
95-200 Pabianice
Poland
This medicine is authorised in the Member States of the European Economic Area under the following names:
| Marketing authorisation name | |
Bulgaria | ????????? 250 mg ????????? ???????? ????????? 500 mg ????????? ???????? | |
Czech Republic | GRUMABIX | |
Denmark | GRUMABIX | |
Germany | GRUMABIX | |
Spain | Grumabix 250 mg film-coated tablets EFG Grumabix 500 mg film-coated tablets EFG | |
France | GRUMABIX 250 mg, film-coated tablet ABIRATERONE ARROW 500 mg, film-coated tablet | |
Italy | GRUMABIX | |
Hungary | GRUMABIX 250 mg filmtabletta GRUMABIX 500 mg filmtabletta | |
Poland | GRUMABIX | |
Slovakia | GRUMABIX |
Date of last revision of this leaflet: December 2022
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/.